title: Should patient groups be more transparent about their funding?
authors.forename: Sophie
authors.initials: S
authors.lastname: Arie
authors.forename: Chris
authors.initials: C
authors.lastname: Mahony
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D002185:Cannabidiol / Q000627:therapeutic use*; D002202:Capital Financing; D002608:Charities / Q000191:economics*; D013759:Dronabinol / Q000627:therapeutic use*; D004338:Drug Combinations; D004345:Drug Industry; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012657:Self-Help Groups / Q000191:economics; D006113:United Kingdom
chemical_list: D000700:Analgesics; D004338:Drug Combinations; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols